Full-Time

Manufacturing Technician 3

Weekend Day Shift

Updated on 8/5/2026

Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

Compensation Overview

€43.1k - €55.8k/yr

+ 15% weekend shift premium

Athenry, Co. Galway, Ireland

In Person

The role requires 10% travel and transitions to a 12-hour backend day-shift schedule in Q4 2026.

Bachelor's

Category
Mechanical Engineering (2)
,
Required Skills
Robotics

Get referred to Dexcom

See people who can refer or advise you

Requirements
  • A Level 6/7 qualification and 5–8 years of related experience are required.
  • Ability to read, analyse, and interpret common scientific and technical documents related to equipment specifications.
  • Ability to write routine reports, pass-downs, and correspondence.
  • Ability to effectively present information and respond to questions from supervisors, engineers, and managers.
  • Knowledge of and experience with programmable logic controllers and automated production/process equipment.
  • Experience with process-improvement projects, including improving yields and reducing downtime.
  • Ability to work hands-on in a fast-paced environment.
  • Knowledge of high-reliability, high-volume manufacturing equipment and processes.
  • Technical writing skills applied to manufacturing documentation and process development, including creation and revision of technical documentation.
  • Ability to perform assigned tasks with appropriate safety practices.
Responsibilities
  • Provide technical support to equipment engineers for the improvement, installation, validation, and transfer of replicate custom automated equipment used in manufacturing scale-up.
  • Support cross-functional equipment deployment teams while working with outside suppliers to meet equipment specifications and timelines.
  • Use schematics, diagrams, written and verbal descriptions, layouts, or defined plans to perform testing, checkout, and troubleshooting.
  • Test the performance of electromechanical assemblies using test equipment.
  • Operate, test, and maintain robotic equipment and vision systems.
  • Analyse and record test results and prepare written documentation.
  • Perform operational testing and fault isolation on automated systems and equipment.
  • Carry out equipment-development activities under the supervision of the project engineer, including assembly and testing of equipment, fixtures, processes, and electronics, and completion of engineering studies and validations.
  • Follow the Safety and Lockout/Tagout program.
  • Update equipment-related documentation, including manuals, drawings, and specifications.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience with pneumatics, hydraulics, electromechanical systems, and resistance welders.
  • Excellent written and verbal communication and personal interaction skills.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dexcom secured coverage for seven million non-insulin patients across major U.S. PBMs.
  • Q2 2026 revenue reached $1.31 billion; management raised full-year guidance to $5.25 billion.
  • Health Canada cleared G7 15 Day, and international Stelo expansion starts in 2026.

What critics are saying

  • Dexcom faces 2025 FDA warning, Class I recalls, and 2026 class-action litigation.
  • Abbott’s Libre remains the main rival, pressuring Dexcom’s pricing, share, and physician loyalty.
  • G8 depends on 2027 FDA filing; any sensor failure or delay damages credibility.

What makes Dexcom unique

  • Dexcom’s G7 15-day sensor extends wear to 15.5 days and lowers sensor swaps.
  • Stelo gives Dexcom direct-to-consumer non-insulin entry, expanding beyond prescription diabetes management.
  • Dexcom’s ecosystem now bundles CGM, CLARITY analytics, and Nutrisense nutrition coaching.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Jul 31st, 2026
DexCom secures coverage for 7M patients, raises growth guidance after Q2 2026 results

DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.

Yahoo Finance
Jul 31st, 2026
DexCom's Q2 revenue climbs 13% to $1.31B, raises full-year guidance to $5.25B

DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.

Yahoo Finance
Jul 30th, 2026
Dexcom raises annual revenue forecast to $5.25B on strong glucose monitor demand

Dexcom raised its full-year revenue forecast on Thursday, driven by strong demand for its continuous glucose monitors. The medical device maker now expects annual revenue between $5.18 billion and $5.25 billion, up from its previous range of $5.16 billion to $5.25 billion. The company reported second-quarter revenue of $1.31 billion, a 13% increase year-over-year, beating analyst estimates of $1.29 billion. Adjusted profit reached 70 cents per share, surpassing the 61-cent estimate. Rising awareness of diabetes care, improved insurance coverage, and consumer preference for finger-prick-free technology have boosted demand for continuous glucose monitors. Dexcom competes in this market alongside Medtronic and Abbott Laboratories. Following the announcement, Dexcom's shares rose over 4% in extended trading.

Ticker Report
Jul 20th, 2026
SEB Asset Management AB Makes New $23.68 Million Investment in DexCom, Inc. $DXCM

SEB Asset Management AB purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 377,064 shares of the medical device company’s stock, valued at approximately $23,680,000. A number of other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a […]

Yahoo Finance
Jul 13th, 2026
Dexcom G7 15 Day wins Health Canada approval as longest-lasting CGM with 15.5 days of wear

Dexcom has received Health Canada authorisation for its G7 15 Day Continuous Glucose Monitoring System for adults 18 and older with diabetes. The device provides real-time glucose readings for 15.5 days, making it the longest-lasting CGM system authorised by Health Canada. The system features an overall mean absolute relative difference of 8.0% and requires fewer sensor changes per month than previous models. It includes waterproof design, direct connectivity to Apple Watch, and a 12-hour grace period for sensor replacement. The product is not yet available for purchase. Dexcom Canada said it is focusing on ensuring healthcare providers and patients have proper support and education before launch. More than four million Canadians live with diabetes.